| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019011971 |
| P356 | DOI | 10.1186/S12885-015-1470-Z |
| P932 | PMC publication ID | 4460965 |
| P698 | PubMed publication ID | 26059332 |
| P5875 | ResearchGate publication ID | 278045438 |
| P2093 | author name string | Ian Smith | |
| Gary K Schwartz | |||
| Richard D Carvajal | |||
| Paul D Nathan | |||
| Helen Mann | |||
| P2860 | cites work | Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP | Q24298571 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Mutations in GNA11 in uveal melanoma | Q24625723 | ||
| Oncogenic mutations in GNAQ occur early in uveal melanoma | Q24658558 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial | Q27853021 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Detection of BRAF gene mutation in primary choroidal melanoma tissue | Q28291609 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 | ||
| Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). | Q51052630 | ||
| A recycling framework for the construction of Bonferroni-based multiple tests | Q51856468 | ||
| Incidence of uveal melanoma in Europe. | Q53236384 | ||
| Absence of BRAF and NRAS mutations in uveal melanoma | Q79107430 | ||
| Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. | Q33396664 | ||
| Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. | Q33819083 | ||
| Temozolomide and treatment of malignant glioma. | Q33983627 | ||
| Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance | Q34272199 | ||
| Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34642874 | ||
| Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study | Q34652628 | ||
| Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | Q34827708 | ||
| Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized Therapy | Q35519172 | ||
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models | Q35835097 | ||
| Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. | Q36615986 | ||
| Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2 | Q36646153 | ||
| Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. | Q37330725 | ||
| Effectiveness of treatments for metastatic uveal melanoma. | Q37449310 | ||
| Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience | Q37701881 | ||
| Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma | Q38226856 | ||
| Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death | Q39188117 | ||
| Epidemiologic aspects of uveal melanoma | Q39632521 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Ipilimumab activity in advanced uveal melanoma | Q44998645 | ||
| Very long-term prognosis of patients with malignant uveal melanoma | Q47423812 | ||
| Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma | Q50147228 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | uveal melanoma | Q356372 |
| dacarbazine | Q416975 | ||
| placebo | Q269829 | ||
| selumetinib | Q7448840 | ||
| P304 | page(s) | 467 | |
| P577 | publication date | 2015-06-10 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). | |
| P478 | volume | 15 |
| Q55280433 | A novel combinatorial treatment option for metastatic uveal melanoma. |
| Q33885560 | A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature |
| Q94547499 | Cellular Plasticity in Breast Cancer Progression and Therapy |
| Q26770492 | Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition) |
| Q38718726 | Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma |
| Q47317062 | Dual Function of Gold Nanoparticles in Synergism with Mitoxantrone and Microwave Hyperthermia Against Melanoma Cells |
| Q41609825 | Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. |
| Q39145837 | Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma |
| Q38646057 | Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review |
| Q47655869 | ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells |
| Q92756955 | Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial |
| Q40251215 | Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion |
| Q56889985 | MEK inhibitors for the treatment of NRAS mutant melanoma |
| Q53143589 | Malignant intraorbital tumor: Primary tumor or metastasis? |
| Q26738377 | Metastatic disease from uveal melanoma: treatment options and future prospects |
| Q38598958 | NRAS-mutant melanoma: current challenges and future prospect |
| Q64913613 | New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. |
| Q52630972 | Obstacles to improving outcomes in the treatment of uveal melanoma. |
| Q47571643 | Recent advances in uveal melanoma treatment. |
| Q38798084 | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives |
| Q55091535 | Selumetinib-based therapy in uveal melanoma patient-derived xenografts. |
| Q61805822 | Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma |
| Q37742632 | The biology of uveal melanoma |
Search more.